Astellas Pharma (OTCMKTS:ALPMY) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

A number of other analysts also recently issued reports on the stock. Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a report on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Astellas Pharma Trading Down 1.3%

ALPMY stock opened at $15.78 on Tuesday. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $16.95. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84. The company has a market capitalization of $28.56 billion, a price-to-earnings ratio of 13.26 and a beta of 0.15. The business has a 50 day simple moving average of $15.24 and a two-hundred day simple moving average of $13.17.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.21 billion. Research analysts anticipate that Astellas Pharma will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).